Many New Products For Forest, But Not Enough To Fill The Lexapro Gap
This article was originally published in The Pink Sheet Daily
Executive Summary
The launches of Tudorza for COPD and Linzess for irritable bowel syndrome are off to strong starts, Forest executives said during the company’s fiscal fourth quarter sales and earnings call. But despite those and other recent entries, the company reported a net loss for the year after revenues nose-dived from the loss of Lexapro.
You may also be interested in...
Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal
Spain’s leading pharma company will use proceeds of its respiratory products sale to bulk up in dermatology, with the aim of becoming a global leader in the sector.
NICE Nod For Selincro May Give Lundbeck Much Needed Revenue Boost
NICE's positive recommendation for Lundbeck's Selincro for alcohol dependence should give the Danish biotech a revenue boost and help offset expiry of its Lexapro/Cipralex patent.
Actavis’ Big Bet On A Diversified Hybrid Model
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.